Cornea Research Foundation of America   Report issue

Foundation Phase 3 Phase 4
Founded: Indianapolis IN United States (1988)

Organization Overview

First Clinical Trial
2009
NCT00912509
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cornea Research Foundation of America

Active Ingredients

Drugs in Phase 4 Trials (2)

loteprednol (lotemax) (1 trial)

prednisone (meticorten) (1 trial)

Drugs in Phase 3 Trials (3)

amphotericin b (fungizone) (1 trial)

netarsudil (2 trials)

riboflavin (2 trials)

Drugs in Other Trials (1)

retaane (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Corneal Edema (Phase 4)

Fuchs' Endothelial Dystrophy (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 6